information, may diminish incentives to conduct research, and could chill manufacturer incentives to introduce new products to the market.[5] And I agree with the observation of my colleague Commissioner Chopra in his statement that ''[b]aseless claims give patients false hope, improperly increase or divert their medical spending, and undermine 'a competitor's ability to compete' on honest attributes.'' [6] Although I support these cases, I hope that the Commission's actions here, which challenge wholly unsubstantiated disease claims, do not discourage research into the potential legitimate benefits of CBD and a wide array of other products. In addition, going forward, I urge the Commission to focus our scarce resources on marketers that make strong, express claims about diseases and serious health issues with little to no scientific support and engage in deceptive practices that cause substantial consumer injury.

[FR Doc. 2020–29003 Filed 12–30–20; 8:45 am]

BILLING CODE 6750–01–P

[5] *See, e.g.,* Statement of Commissioner Maureen K. Ohlhausen, *In the Matter of Health Discovery Corporation and FTC* v. *Avrom Boris Lasarow, et al.* (Feb. 2015), *https://www.ftc.gov/public-statements/2015/02/dissenting-statement-commissioner-maureen-k-ohlhausen-matter-health;* Statement of Commissioner Joshua D. Wright, *FTC* v. *Kevin Wright; HCG Platinum, LLC; and Right Way Nutrition, LLC* (Dec. 2014), *https://www.ftc.gov/public-statements/2014/12/statement-commissioner-joshua-d-wright-federal-trade-commission-v-kevin;* Statement of Commissioner Joshua D. Wright, *In the Matter of GeneLink, Inc., and foru International Corporation* (January 2014), *https://www.ftc.gov/public-statements/2014/01/statement-commissioner-joshua-d-wright-matter-genelink-inc-foru;* Statement of Commissioner Maureen K. Ohlhausen Dissenting in Part and Concurring in Part, *In the Matter of GeneLink, Inc. and foru International Corporation* (January 2014), *https://www.ftc.gov/public-statements/2014/01/statement-commissioner-maureen-k-ohlhausen-dissenting-part-concurring-part;* Dissenting Statement of Commissioner Maureen K. Ohlhausen, *FTC* v. *Springtech 77376, et al.* (July 2013), *https://www.ftc.gov/public-statements/2013/07/dissenting-statement-commissioner-maureen-k-ohlhausen; see also* J. Howard Beales, III and Timothy J. Muris, In Defense of the *Pfizer* Factors, George Mason Law & Economics Research Paper No. 12–49 (May 2012), available at: *https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2087776.*

[6] *See* Statement of Commissioner Rohit Chopra Regarding the Cannabidiol (CBD) Enforcement Actions (Dec. 17, 2020).

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30 Day–21–1277]

Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled The Childcare Survey of Activity and Wellness (C–SAW) Pilot Study to the Office of Management and Budget (OMB) for review and approval. CDC previously published a ''Proposed Data Collection Submitted for Public Comment and Recommendations'' notice on October 30, 2020 to obtain comments from the public and affected agencies. CDC received one public comment related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication.

Proposed Project

The Childcare Survey of Activity and Wellness (C–SAW) Pilot Study (OMB Control No. 0920–1277, Exp. 12/31/2020)—Revision—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The Centers for Disease Control and Prevention (CDC) work to promote optimal nutrition, physical activity, and wellness in early care and education (ECE) facilities for children 0–5 years of age. Data collected from this pilot survey will be used to understand the current practices of ECE centers in a representative sample in four states. The survey will also be used to inform the development of a potential national surveillance system.

A sample of approximately 1,266 ECE centers across four states will be selected to participate in this one-time data collection effort. However, it is estimated that approximately 10% of the original sample will be out of business or otherwise ineligible yielding an actual sample of 1,140 ECEs to be recruited. Each center will receive a recruitment letter introducing the survey, and instructions for completing the survey. It is anticipated that most responses will be submitted through the web. However, paper surveys will be available upon request. It is also anticipated that the response rate will be approximately 55% based on a review of recent surveys of childcare centers conducted by the Federal government. Thus, we anticipate the number of completed surveys to be 627. CDC requests approval for a two year period with an estimated 513 total Burden Hours. Participation in this study is completely voluntary and there are no costs to the respondent other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
ECE Director or Administrator	Recruitment Letter	1,140	1	5/60
ECE Director or Administrator	Web/Mail Survey	627	1	40/60

Jeffery M. Zirger,

Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2020–28982 Filed 12–30–20; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Requirement for Negative Pre-Departure COVID–19 Test Result for All Airline Passengers Arriving Into the United States From the United Kingdom

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of Agency Order.

SUMMARY: The Centers for Disease Control and Prevention (CDC), a component of the U.S. Department of Health and Human Services (HHS), announces an Agency Order requiring negative pre-departure COVID–19 test results for all airline passengers arriving into the United States from the United Kingdom (UK). This Order is issued to preserve human life; prevent the further introduction, transmission, and spread of the virus that causes COVID–19 into the United States, including new virus variants; preserve the health and safety of airline crew members, passengers, airport personnel, and communities; and preserve hospital, healthcare, and emergency response resources within the United States.

DATES: This Order was effective December 27, 2020 at 7:01 p.m. EST (12:01 a.m. December 28, 2020 GMT). See **SUPPLEMENTARY INFORMATION** for the conditions under which the Order will expire.

FOR FURTHER INFORMATION CONTACT: Jennifer Buigut, Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H16–4, Atlanta, GA 30329. Email: *dgmqpolicyoffice@cdc.gov.*

SUPPLEMENTARY INFORMATION: On December 14, 2020, Public Health England announced that a new variant of SARS-CoV–2 had been identified across the southeast of England (*i.e.,* Kent and the surrounding areas). While it is known and expected that viruses change through mutation leading to the emergence of new variants, preliminary analysis in the UK suggests that this SARS–CoV–2 variant may be more transmissible than previously circulating variants. Pre-departure testing may detect travelers infected with SARS–CoV–2 before they initiate their travel and may reduce the risk of transmission. Therefore, urgent efforts are needed to mitigate the potential spread of this new virus variant into the United States.

This Order establishes requirements for (1) airlines arriving into the United States from the UK; and (2) passengers departing the United Kingdom with a final destination in the United States.

A copy of the Order and Attachment A are provided below and a copy of the signed order can be found at *https://www.cdc.gov/quarantine/testing-requirement-for-arriving-UK-air-travelers.html.*

Centers for Disease Control and Prevention Department of Health and Human Services

Order Under Section 361 of the Public Health Service Act (42 U.S.C. 264) and 42 Code of Federal Regulations 71.20 & 71.31(b)

Requirement for Negative Pre–Departure Covid–19 Test Result for All Airline Passengers Arriving Into the United States From the United Kingdom (UK)

Summary

Pursuant to 42 CFR 71.20 and as set forth in greater detail below, this Notice and Order prohibit the introduction into the United States of any airline passenger departing from the UK unless the passenger has a negative pre-departure test result for COVID–19. The test must be a viral test that was conducted on a specimen collected during the 3 calendar days preceding the flight's departure (Qualifying Test). Passengers must retain written or electronic documentation reflecting the negative Qualifying Test result presented to the airline and produce such results upon request to any U.S. government official or a cooperating state or local public health authority.

Pursuant to 42 CFR 71.31(b) and as set forth in greater detail below, this Notice and Order constitutes a controlled free pratique to any airline with an aircraft arriving into the United States from the UK. Pursuant to the controlled free pratique, the airline must comply with the following conditions in order to receive permission for the aircraft to enter and disembark passengers in the United States:

- Airline must verify that every passenger—2 years of age or older—onboard the flight has attested to having received a negative Qualifying Test result.
- Airline must confirm that every passenger onboard the aircraft has documentation reflecting a negative Qualifying Test result.

Statement of Intent

This Order shall be interpreted and implemented in a manner as to achieve the following paramount objectives:

- Preservation of human life;
- Preventing the further introduction, transmission, and spread of the virus that causes COVID–19 into the United States, including new virus variants;
- Preserving the health and safety of airline crew members, passengers, airport personnel, and communities; and
- Preserving hospital, healthcare, and emergency response resources within the United States.

Definitions

Airline shall have the same definition as under 42 CFR 71.1(b).

Attest/Attestation means having completed the attestation in Attachment A. Such attestation may be completed in written or electronic form. The attestation is a statement, writing, entry, or other representation under 18 U.S.C. 1001.

Confirm that every passenger onboard the aircraft has documentation reflecting a negative Qualifying Test result means confirmation that:

(1) The personal identifiers (*e.g.,* name and date of birth) on the Qualifying Test result match the